Atorvastatin calcium hydrate
Based on 69 publication(s) in Google Scholar
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
For research use only. We do not sell to patients.
- Purity: 99.83%
- CAS No.: 344423-98-9
- Formula: C33H35FN2O5.1/2Ca.3/2H2O
- Molecular Weight:605.71
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Atorvastatin calcium hydrate
More- Signal Transduct Target Ther. 2025 Nov 12;10(1):366. [Abstract]
- Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]
- Nat Metab. 2025 Oct;7(10):2142-2164. [Abstract]
- Nat Aging. 2025 Aug 26. [Abstract]
- Nat Neurosci. 2026 Jun;29(6):1369-1385. [Abstract]
- Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. [Abstract]
- Adv Sci (Weinh). 2024 Sep;11(34):e2403451. [Abstract]
- MedComm (2020). 2024 Aug 31;5(9):e681. [Abstract]
- Cell Death Dis. 2021 May 13;12(5):482. [Abstract]
- Cancer Lett. 2023 Jan 1:552:215976. [Abstract]
- Cell Commun Signal. 2026 Mar 23;24(1):259. [Abstract]
- Phytomedicine. 2025 Oct:146:157128. [Abstract]
- Phytomedicine. 2025 Jul:142:156713. [Abstract]
- Phytomedicine. 2023 Jul 26;119:154997. [Abstract]
- Acta Pharmacol Sin. 2024 Jun;45(6):1316-1320. [Abstract]
- Oncogene. 2022 Dec;41(49):5266-5278. [Abstract]
- Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. [Abstract]
- Free Radic Biol Med. 2024 Aug 1:220:179-191. [Abstract]
- Environ Sci Technol Lett. 2025 Apr 8.
- Emerg Microbes Infect. 2025 Dec;14(1):2470371. [Abstract]
- Pharmaceutics. 2022 Jan 12;14(1):176. [Abstract]
- Eur J Med Chem. 2024 Dec 5:279:116842. [Abstract]
- Life Sci. 2025 Jun 1:370:123571. [Abstract]
- Front Bioeng Biotechnol. 2022 Mar 17;10:826093. [Abstract]
- Eur J Pharmacol. 2025 Apr 5:992:177357. [Abstract]
- Eur J Pharmacol. 2024 Feb 5:964:176261. [Abstract]
- Eur J Pharmacol. 2023 Oct 5:956:175938. [Abstract]
- Int Immunopharmacol. 2026 Apr 1:174:116346. [Abstract]
- Int Immunopharmacol. 2026 Apr 1:174:116259. [Abstract]
- Int Immunopharmacol. 2025 Dec 3:166:115644. [Abstract]
- Int J Mol Sci. 2023 Apr 19;24(8):7492. [Abstract]
- Front Pharmacol. 2025 Apr 30:16:1573032. [Abstract]
- Inflammation. 2024 Oct 31. [Abstract]
- Front Cell Dev Biol. 2022 Mar 3;10:806081. [Abstract]
- Chem Biol Interact. 2025 Oct 22:420:111671. [Abstract]
- Clin Pharmacol Ther. 2025 Jul 14. [Abstract]
- Sci Rep. 2020 Jan 28;10(1):1308. [Abstract]
- Exp Neurol. 2025 Sep:391:115305. [Abstract]
- Ann N Y Acad Sci. 2026 Mar;1557(1):e70224. [Abstract]
- FASEB J. 2026 May 15;40(9):e71873. [Abstract]
- Nanomedicine (Lond). 2026 Mar;21(6):789-801. [Abstract]
- Med Gas Res. 2025 Mar 1;15(1):148-155. [Abstract]
- J Virol. 2026 Jun 9:e0030126. [Abstract]
- Proteomics. 2023 Aug;23(16):e2300041. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3659-3670. [Abstract]
- J Tradit Complement Med. 2024 Mar 29;14(6):656-665. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- Cell Cycle. 2021 Oct;20(20):2160-2173. [Abstract]
- Cell Cycle. 2019 Dec;18(23):3337-3350. [Abstract]
- Endocrinology. 2022 Jul 1;163(7):bqac076. [Abstract]
- Endocrinology. 2018 May 1;159(5):2008-2021. [Abstract]
- J Nat Prod. 2022 Jul 22;85(7):1738-1750. [Abstract]
- Arch Biochem Biophys. 2025 Mar:765:110316. [Abstract]
- Exp Cell Res. 2023 Dec 15;433(2):113829. [Abstract]
- Acta Diabetol. 2025 Mar 27. [Abstract]
- J Appl Toxicol. 2024 Aug;44(8):1198-1213. [Abstract]
- J Neuroimmunol. 2021 Jan 15:350:577429. [Abstract]
- FEBS Open Bio. 2025 Aug 8. [Abstract]
- J Mol Neurosci. 2022 Mar;72(3):565-573. [Abstract]
- Oncologie. 2025 May 26.
- SSRN. 2026 May 20.
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Apr 9.
- Orebro University. 2024.
- bioRxiv. 2024 Jul 3:2024.07.01.601474. [Abstract]
- Research Square Preprint. 2024 Apr 9.
- Biomed Pharmacother. 2023 Oct:166:115323. [Abstract]
- Research Square Preprint. 2022 Jun.
- Research Square Preprint. 2021 Dec.
-
Flow Cytometry
-
ELISA
-
In Vivo Efficacy Study
-
WB
-
Histological Imaging/Staining
Biological Activity
Atorvastatin calcium salt trihydrate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 344423-98-9
-
Appearance Solid
-
Molecular Weight 605.71
-
Formula C33H35FN2O5.1/2Ca.3/2H2O
-
Color White to off-white
-
SMILES
O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4.[1/2].[3/2].[Ca].O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (69)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2025 Nov 12;10(1):366. PMID: 41219186 -
Signal Transduct Target Ther
2023 Dec 25;8(1):457. PMID: 38143263
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]
EGFRvIII-high U87 cells were cocultured with EGFRvIII-CAR-T cells and treated with Atorvastatin (5 μM, 3 days) or Cytochalasin D (10 μg/mL, 1 day). Immunoblotting of magnetically separated cells showed that both drugs alleviated CAR molecule transfer (representative of three independent experiments).
-
Nat Metab
2025 Oct;7(10):2142-2164. PMID: 40983680
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Oct;7(10):2142-2164. [Abstract]
Representative histogram and quantification of normalized MHC I membrane levels determined by flow cytometry (stained for anti-HLA-A, anti-HLA-B and anti-HLA-C) in response to indicated treatment conditions in iAstrocytes (N = 4–6; three (control and cholesterol) or two (Atorvastatin hemicalcium salt) independent experiments from two isogenic sets. Data are shown as the mean. *P < 0.05 (two-sided one-sample t-test for cholesterol and atorvastatin versus 1).
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Oct;7(10):2142-2164. [Abstract]
Secreted Il-6 levels in medium of ApoE3 iAstrocytes that were pretreated with or without exogenous Cholesterol (10 μM) or Atorvastatin hemicalcium salt (0.5 μM) for 1 h before 24-h cotreatment with increasing doses of TNF, IL-1α and C1q.
-
Nat Aging
2025 Aug 26. PMID: 40858817 -
Nat Neurosci
Amyloid-β-driven glymphatic dysfunction in Alzheimer's disease model mice is driven by Ca2+-mediated increases in astrocytic cholesterol. [Abstract]2026 Jun;29(6):1369-1385. PMID: 41986732 -
Mol Cell
The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. [Abstract]2021 Jul 1;81(13):2736-2751.e8. PMID: 33932349
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. [Abstract]
Tumor volumes of indicated patient-derived xenografts (PDXs) treated with Atorvastatin (40 mg/kg, i.p., every two days for 30 days).
-
Adv Sci (Weinh)
Short-Term Statin Therapy Induces Hepatic Insulin Resistance Through HNF4α/PAQR9/PPM1α Axis Regulated AKT Phosphorylation. [Abstract]2024 Sep;11(34):e2403451. PMID: 38970167
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Sep;11(34):e2403451. [Abstract]
Representative images of p-AKT1 staining of liver sections of the DMSO, Simvastatin and Atorvastatin hemicalcium salt (20 mg/kg, 3 days, atorvastatin with HFD)‐treated mice.
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Sep;11(34):e2403451. [Abstract]
Western blotting of PAQR9 in mouse primary hepatocytes under the treatment of DMSO, Simvastatin (Sim), Atorvastatin hemicalcium salt (Ator, 10 mmol/L, 24-48 h) and Rosuvastatin (Rosu).
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Sep;11(34):e2403451. [Abstract]
The top 20 predicted transcription factors of differentially expressed genes under Atorvastatin hemicalcium salt treatment. The gene expression data were from GEO datasets GSE24188 and the TF prediction was by ChEA3. The bar showed rank score and the line showed the number of overlapped genes.
-
MedComm (2020)
Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [Abstract]2024 Aug 31;5(9):e681. PMID: 39220103 -
Cell Death Dis
Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. [Abstract]2021 May 13;12(5):482. PMID: 33986254 -
Cancer Lett
Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. [Abstract]2023 Jan 1:552:215976. PMID: 36272615
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Jan 1:552:215976. [Abstract]
Panc-1 and MIA PaCa-2 cells were treated with Atorvastatin (20 μM or 50 μM) for 24 h. FOXM1 and mutant p53 protein levels were measured in different treatment groups.
-
Cell Commun Signal
Atorvastatin promotes lipid catabolism in colorectal cancer via FDFT1‒mediated inhibition of the PI3K/AKT pathway. [Abstract]2026 Mar 23;24(1):259. PMID: 41866501 -
Phytomedicine
Mori fructus-derived extracellular vesicle-like nanoparticles regulate dyslipidemia and prevent atherosclerosis progression via miRNAs. [Abstract]2025 Oct:146:157128. PMID: 40815949
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157128. [Abstract]
ApoE-/- mice were administrated with high-fat-diet accompanied by MFEVLPs (5 or 50 μg/d, i.p) or Atorvastatin (10 mg/kg/day, i.g) for 12 weeks.
-
Phytomedicine
Bioactive equivalent combinatorial components of Xiao-Xu-Ming decoction inhibit the calmodulin-mediated MLCK/MLC axis to attenuate coronary artery spasm. [Abstract]2025 Jul:142:156713. PMID: 40349422 -
Phytomedicine
Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade. [Abstract]2023 Jul 26;119:154997. PMID: 37523836 -
Acta Pharmacol Sin
2024 Jun;45(6):1316-1320. PMID: 38459255 -
Oncogene
Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc. [Abstract]2022 Dec;41(49):5266-5278. PMID: 36316442
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Dec;41(49):5266-5278. [Abstract]
ATP assay. The combination of Atorvastatin (2.5, 5, 10, 20 μM; 48 h) and SR1078 synergistically inhibits CRC cell viability.
-
Arterioscler Thromb Vasc Biol
N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. [Abstract]2022 May;42(5):644-658. PMID: 35296150 -
Free Radic Biol Med
Atorvastatin combined with imipenem alleviates lung injury in sepsis by inhibiting neutrophil extracellular trap formation via the ERK/NOX2 signaling pathway. [Abstract]2024 Aug 1:220:179-191. PMID: 38704053 -
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Environ Sci Technol Lett. 2025 Apr 8.
The hCMEC-D3 cells were exposed to 0.01 μM 77PD-Q for 24 h in the presence or absence of 0.3 μM Atorvastatin (0.3 μM, 24 h).
-
Emerg Microbes Infect
SREBP2-dependent lipid droplet formation enhances viral replication and deteriorates lung injury in mice following IAV infection. [Abstract]2025 Dec;14(1):2470371. PMID: 39968754 -
Pharmaceutics
Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. [Abstract]2022 Jan 12;14(1):176. PMID: 35057070 -
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Life Sci
CKN reduces TLR4-mediated inflammation and cerebral I/R injury by activating the LXRα/ABCA1 pathway in microglia. [Abstract]2025 Jun 1:370:123571. PMID: 40107493 -
Front Bioeng Biotechnol
Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]2022 Mar 17;10:826093. PMID: 35372314 -
Eur J Pharmacol
Protective effects of atorvastatin on testicular dysfunction and reduced sperm quality induced by high-fat diet in mice: The inhibitory mechanism of oxidative stress. [Abstract]2025 Apr 5:992:177357. PMID: 39921059 -
Eur J Pharmacol
Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis. [Abstract]2024 Feb 5:964:176261. PMID: 38141938 -
Eur J Pharmacol
DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE-/- mice via suppressing inflammation, endothelial necroptosis and apoptosis. [Abstract]2023 Oct 5:956:175938. PMID: 37536623 -
Int Immunopharmacol
Milk exosomes loaded with atorvastatin suppress fibroblast activation and extracellular matrix remodeling via the TGF-β/SMAD pathway in ligamentum flavum hypertrophy. [Abstract]2026 Apr 1:174:116346. PMID: 41707594 -
Int Immunopharmacol
High-cholesterol-load-triggered pyroptosis of gingival fibroblasts promotes periodontitis. [Abstract]2026 Apr 1:174:116259. PMID: 41707588 -
Int Immunopharmacol
Structural polysaccharide PCP1 from Polygonatum cyrtonema Hua attenuates atherosclerosis via dual-target suppression of CD36/MSR1 and TLR4/NF-κB pathways. [Abstract]2025 Dec 3:166:115644. PMID: 41045802 -
Int J Mol Sci
Effects of Dietary Cholesterol Regulation on Spermatogenesis of Gobiocypris rarus Rare Minnow. [Abstract]2023 Apr 19;24(8):7492. PMID: 37108655 -
Front Pharmacol
Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells. [Abstract]2025 Apr 30:16:1573032. PMID: 40371351 -
Inflammation
2024 Oct 31. PMID: 39480573 -
Front Cell Dev Biol
Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]2022 Mar 3;10:806081. PMID: 35309902 -
Chem Biol Interact
Subchronic exposure to CeCl3 promotes macrophage ferroptosis and atherosclerotic plaque formation by inhibiting the Keap1/Nrf2/GPX4 pathway. [Abstract]2025 Oct 22:420:111671. PMID: 40706741 -
Clin Pharmacol Ther
Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™). [Abstract]2025 Jul 14. PMID: 40657937 -
Sci Rep
Scutellarin inhibition of the rosuvastatin uptake in rat hepatocytes and the competition for organic anion transporting polypeptide 1B1 in HEK293T cells. [Abstract]2020 Jan 28;10(1):1308. PMID: 31992796 -
Exp Neurol
Salvianolic acid B exerts cerebroprotective effects after traumatic brain injury via Nrf2-dependent antioxidant and anti-inflammatory cascades. [Abstract]2025 Sep:391:115305. PMID: 40383364 -
Ann N Y Acad Sci
The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. [Abstract]2026 Mar;1557(1):e70224. PMID: 41774091 -
FASEB J
Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]2026 May 15;40(9):e71873. PMID: 42087353 -
Nanomedicine (Lond)
Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction. [Abstract]2026 Mar;21(6):789-801. PMID: 41660754 -
Med Gas Res
The augment effects of magnesium hydride on the lipid lowering effect of atorvastatin: an in vivo and in vitro investigation. [Abstract]2025 Mar 1;15(1):148-155. PMID: 39436189 -
J Virol
The cholesterol transporter Niemann-Pick C1 facilitates the entry of porcine epidemic diarrhea coronavirus. [Abstract]2026 Jun 9:e0030126. PMID: 42262129 -
Proteomics
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]2023 Aug;23(16):e2300041. PMID: 37140101 -
Naunyn Schmiedebergs Arch Pharmacol
Bisdemethoxycurcumin suppresses the progression of atherosclerosis and VSMC-derived foam cell formation by promoting lipophagy. [Abstract]2023 Dec;396(12):3659-3670. PMID: 37289282 -
J Tradit Complement Med
Zhilong Huoxue Tongyu capsule protects against atherosclerosis by suppressing EndMT via modulating Hippo/YAP signaling pathway. [Abstract]2024 Mar 29;14(6):656-665. PMID: 39850597 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Cell Cycle
Atorvastatin inhibited TNF-α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-κB signaling. [Abstract]2021 Oct;20(20):2160-2173. PMID: 34494933 -
Cell Cycle
Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. [Abstract]2019 Dec;18(23):3337-3350. PMID: 31599189 -
Endocrinology
2022 Jul 1;163(7):bqac076. PMID: 35583599 -
Endocrinology
miR-1224-5p Enhances Hepatic Lipogenesis by Targeting Adenosine Monophosphate-Activated Protein Kinase α1 in Male Mice. [Abstract]2018 May 1;159(5):2008-2021. PMID: 29474539
Atorvastatin calcium hydrate purchased from MedChemExpress. Usage Cited in: Endocrinology. 2018 May 1;159(5):2008-2021. [Abstract]
Male C57BL/6 mice are intragastrically treated with Atorvastatin (0.1 mg/kg/day) and placebo for 10 weeks in the presence of HFD after 10-week-HFD feeding and then sacrificed for sample collection. H&E and oil red O staining of frozen liver sections.
-
J Nat Prod
Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway. [Abstract]2022 Jul 22;85(7):1738-1750. PMID: 35749236 -
Arch Biochem Biophys
Astaxanthin-loaded polylactic acid-glycolic acid nanoparticles alleviates atherosclerosis by suppressing macrophage ferroptosis via the NRF2/SLC7A11/GPX4 pathway. [Abstract]2025 Mar:765:110316. PMID: 39848420 -
Exp Cell Res
Rapamycin promotes hematoma resorption and enhances endothelial cell function by suppressing the mTOR/STAT3 signaling in chronic subdural hematoma. [Abstract]2023 Dec 15;433(2):113829. PMID: 37879548 -
Acta Diabetol
Identification of FLVCR1 as the iron metabolism-related gene of statin-associated diabetes. [Abstract]2025 Mar 27. PMID: 40146399 -
J Appl Toxicol
2024 Aug;44(8):1198-1213. PMID: 38639436 -
J Neuroimmunol
The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. [Abstract]2021 Jan 15:350:577429. PMID: 33176238 -
FEBS Open Bio
Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]2025 Aug 8. PMID: 40781787 -
J Mol Neurosci
Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages. [Abstract]2022 Mar;72(3):565-573. PMID: 34569007 -
-
-
-
-
-
bioRxiv
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases uncovers cholesterol as a regulator of astrocyte reactivity impaired by ApoE4. [Abstract]2024 Jul 3:2024.07.01.601474. PMID: 39005258 -
-
Biomed Pharmacother
2023 Oct:166:115323. PMID: 37579692 -
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (165.10 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (8.25 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (251 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6510 mL | 8.2548 mL | 16.5096 mL | 41.2739 mL |
| 5 mM | 0.3302 mL | 1.6510 mL | 3.3019 mL | 8.2548 mL | |
| 10 mM | 0.1651 mL | 0.8255 mL | 1.6510 mL | 4.1274 mL | |
| 15 mM | 0.1101 mL | 0.5503 mL | 1.1006 mL | 2.7516 mL | |
| 20 mM | 0.0825 mL | 0.4127 mL | 0.8255 mL | 2.0637 mL | |
| 25 mM | 0.0660 mL | 0.3302 mL | 0.6604 mL | 1.6510 mL | |
| 30 mM | 0.0550 mL | 0.2752 mL | 0.5503 mL | 1.3758 mL | |
| 40 mM | 0.0413 mL | 0.2064 mL | 0.4127 mL | 1.0318 mL | |
| 50 mM | 0.0330 mL | 0.1651 mL | 0.3302 mL | 0.8255 mL | |
| 60 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.6879 mL | |
| 80 mM | 0.0206 mL | 0.1032 mL | 0.2064 mL | 0.5159 mL | |
| 100 mM | 0.0165 mL | 0.0825 mL | 0.1651 mL | 0.4127 mL |